Cytokinetics (CYTK) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.50
- Estimate
- -$1.59
- Surprise
- +5.4%
- Revenue (period 2026-06-30)
- $28.6M
- Score today
- 5.3/10
Revenue source: xbrl.
How the report landed
Cytokinetics (CYTK) reported a narrower loss than forecast — adjusted EPS of -$1.50 against the -$1.59 estimate (a 5.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CYTK Sell at 5.3/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +5.4% surprise compares with a -0.7% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: MYQORZO
- Concentration risk — Supplier: single source CMOs
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $63.43
- Price target
- $98.95
- Stop
- $59.19
- Upside to target
- +56.0%
- Reward-to-risk
- 8.4:1
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
CYTK at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $8.57B
- P/E (fwd)
- -13.9
- 52-week range
- $54.30–$88.31
- Off 52-week high
- 28.2%
- RSI (14)
- 41
- Volume vs avg
- 0.91×
- Score today
- 5.3/10